Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study
will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are
refractory to conventional therapies. This is an open label study and it's divided into two
parts.
Part 1: This part is ascending dose design to determine the safety and tolerability of VG161
and find recommended dose of VG161.
Part 2: This part is extended dose design to determine the effectiveness of VG161.